Our expert attending
Dedicated professionals committed to clinical excellence.
Meet Southern Star Research at SITC 2026
Southern Star Research will be attending SITC 2026, taking place from 4–8 November 2026 in Phoenix, Arizona.
The Society for Immunotherapy of Cancer (SITC) Annual Meeting brings together researchers, clinicians and industry leaders working across cancer immunology and immunotherapy, with a program spanning basic, translational and clinical research.
If your organisation is developing an oncology or immuno-oncology program and planning its next clinical milestone, we welcome the opportunity to connect during SITC 2026.
Oncology and Immuno-Oncology Clinical Development
Oncology is one of Southern Star Research’s most established therapeutic areas, with experience across Phase I–III studies and a broad range of tumour types.
Our teams bring hands-on Phase I oncology experience, strong investigator relationships and direct access to senior clinical development expertise. Our capabilities span immuno-oncology and monoclonal antibodies, targeted and biomarker-driven therapies, and radiopharmaceutical studies.
For early-phase programs, we support protocol and feasibility planning, site and investigator selection, and the operational requirements of complex oncology studies. Australia provides an established pathway for Phase I and Phase II oncology development, with the opportunity to extend later-phase studies across Asia Pacific.
How We Support Your Clinical Development
- Proactive Partnership: We commit to engaging intellectually and energetically with our clients’ challenges. Our teams apply foresight, critical thinking and domain expertise to anticipate obstacles and contribute meaningfully to the trial’s success.
- Embedded Quality: We define quality not just by compliance, but by the consistent application of judgment, rigour and thoughtful planning throughout all stages of the clinical trial process.
- Tailored Execution: Our flexible, hands-on approach means your study is designed for both scientific and commercial success, tailored to your strategy, timelines and endpoints.
As a mid-sized CRO with strong early-phase capabilities, Southern Star Research supports first-in-human, first-in-patient and Phase I–II clinical trials, as well as later-phase development.
Our focus is on generating high-quality data that meets international regulatory expectations and supports confident decisions as programs progress towards later-stage development, partnerships, licensing and future investment.
Meet Our Team at SITC 2026
Craig Leach, Vice President, Business Development, will be representing Southern Star Research at SITC 2026.
Meet with Craig to discuss upcoming oncology and immuno-oncology programs, early-phase development in Australia, and opportunities to extend clinical development across Asia Pacific.
If you are planning an upcoming study or evaluating the next stage of your clinical program, we welcome the opportunity to connect in Phoenix.
Book a meeting to discuss your clinical development plans.